11 results about "Erythrocytes membrane" patented technology

The present disclosure proposes a preparation method of a vesicle formed by an erythrocyte membrane encapsulating Newcastle disease virus, including: mixing a compacted erythrocyte solution, a phosphate buffered saline (PBS) solution, and Newcastle disease virus (NDV); centrifuging a resulting mixture of erythrocytes added with NDV; and resuspending and precipitating the centrifuged mixture with a PBS solution to obtain the vesicle formed by the erythrocyte membrane encapsulating Newcastle disease virus.

The invention provides application of mitochondrial vesicles in reduction of mitochondrial DNA deletion mutation. The mitochondrial vesicles are prepared by wrapping mitochondria with erythrocyte membranes, the mitochondrial vesicles can be tested and verified to effectively reduce the mitochondrial DNA deletion mutation level in cells, metabolism and functions of mutant cells are improved, verification is further carried out in muscle cells of CPEO patients, and the clinical application prospect is wide. By implanting the mitochondrial vesicles, the mitochondrial DNA deletion mutation level in the CPEO patient muscle cells can be effectively reduced, which indicates that the mitochondrial vesicles have the potential of treating CPEO, and a new thought is provided for treating diseases related to mitochondrial DNA deletion mutation.

The invention belongs to the technical field of tumor drugs, and particularly relates to an intelligent nano bionic drug delivery system based on ZIF-8, a preparation method and application, adriamycin, DNAzyme and an aptamer are loaded on ZIF-8, and the preparation method comprises the steps that after adriamycin is loaded to a ZIF-8 nano carrier, DNAzyme is further adsorbed by means of electrostatic interaction, and the ZIF-8 nano carrier is loaded with the DNAzyme; the intelligent nano bionic drug delivery system based on ZIF-8 is characterized in that a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system is prepared by using a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system, then using an erythrocyte membrane to perform surface modification, and finally inserting an aptamer drug into the surface of the cytomembrane through a lipid insertion method, and the intelligent nano bionic drug delivery system based on ZIF-8 is used for relieving chemotherapy drug resistance and improving the anti-tumor immunity efficiency; and the effect of the medicine in the tumor is improved to the greatest extent.

The invention provides an erythrocyte microreactor as well as a preparation method and application thereof, and belongs to the technical field of biomedical engineering. Glucose oxidase (GOx) is entrapped in erythrocytes under a hypotonic condition, endogenous hemoglobin (Hb) is retained, and palmitate modified catalase (CAT) is fixed on the surface of an erythrocyte membrane, so that the erythrocyte microreactor is prepared. According to the invention, spatial separation and function synergy of enzyme distribution and synergistic effect of GOx / Hb intracellular catalysis and membrane surface CAT removal of by-product H2O2 are realized, cascade reaction efficiency and stability are effectively improved, and accurate regulation and control of NO generation can be realized. Experiments show that the microreactor has remarkable effects in the aspects of regulating NO steady state, improving glucose tolerance, relieving insulin resistance, stabilizing blood glucose and the like, has a lasting curative effect, low medication frequency and high biological safety, and has a wide application prospect in the aspects of biological catalysis and prevention and treatment of metabolic diseases such as diabetes mellitus.

The invention discloses a double-cell membrane fusion carrier and hydrogel synergistic double-drug system as well as preparation and application thereof, and relates to the technical field of biological medicine and tissue engineering. According to the invention, enzyme-triggered synergistic controlled release and MMP-9 enzyme sensitive design are adopted to realize double-drug synchronous sequential release, and an inflammation-osteogenesis repair process is accurately matched; according to the present invention, the BMP-2circRNA half-life period is prolonged to 96 h, the osteogenic gene (Runx2, OCN) expression quantity is increased by 4 times, the osteogenic differentiation is significantly promoted, the targeting and cycle performance is excellent, the RMHM vector mediates bone defect homing through the CXCR4 receptor, and the targeting efficiency is increased by 3.2 times compared with the traditional liposome; the erythrocyte membrane CD47 protein reduces the immunogenicity, the in vivo half-life period is prolonged to 36 hours, and the whole body exposure risk is reduced.

This invention relates to a biomimetic delivery system co-loaded with a radionuclide and a KDM5B degrading agent, its preparation method, and its application. The biomimetic delivery system includes liposomes, KDM5B degrading agent CMATACs encapsulated within the liposomes, and a radionuclide labeled on the surface of the liposomes. 177 Lu, erythrocyte membrane vesicles encapsulating the liposomes, and tumor homing peptide CREKA modified on the surface of the liposomes. Compared with the prior art, this invention achieves for the first time the synergistic delivery of "epigenetic regulation and targeted radionuclide therapy", and the prepared biomimetic delivery system has excellent in vivo anti-tumor effects and biosafety.

The invention discloses an agglutination-free mixed state red blood cell separation medium, a separation method and application, and every 100 mL of the agglutination-free mixed state red blood cell separation medium comprises 5.0 to 10.0 g of glucose, 5.0 to 15.0 g of bovine serum albumin, 0.580 to 0.655 g of disodium hydrogen phosphate, 0.020 to 0.027 g of sodium dihydrogen phosphate, 0.05 to 0.08 mL of a preservative and the balance of ultrapure water. The separation method comprises the following steps: mixing red blood cells with the monoclonal antibody, incubating at a proper temperature and fully reacting, transferring a mixed suspension containing the free red blood cells, washing, adding normal saline to dilute the concentration to 3-5%, and finally standing by using a separating medium to separate the free red blood cells. The method has the characteristics of one-time thorough separation, short separation time, no shrinkage deformation of separated free erythrocyte membranes and high recovery rate, and is suitable for separation of agglutination-free mixed erythrocytes.

The invention aims to provide a preparation method and application of a gouty arthritis diagnosis and treatment integrated bionic nanoprobe, and belongs to the technical field of life medicine and inorganic nanomaterials. An alloy structure formed by gold-platinum nano-clusters is constructed through a chemical reduction method to serve as an inner core of the nano-clusters, and the exterior of the nano-clusters is coated with an erythrocyte membrane to obtain the gold-platinum nano-clusters. The nanoprobe coats an erythrocyte membrane, and is long in cycle half-life period and high in safety. The nanoprobe has uricase-like activity and catalase-like activity, can degrade hydrogen peroxide as a byproduct of uric acid while degrading uric acid, and relieves oxidative stress damage. The enzyme-like activity can be improved through in-vivo and in-vitro mild photothermal therapy, and the treatment effect of the probe on acute gouty arthritis is comprehensively improved.

This invention provides a SNP site for Co(a-b-) blood type that triggers immune hemolytic transfusion reactions, a blood typing kit, a method for identification, and its application, relating to the field of biotechnology. The SNP site includes a c.168delC deletion mutation at position 168, starting from the start codon in the AQP1 gene coding region. This mutation is a pathogenic SNP site for Co(a-b-) blood type, and the alleles it forms prevent the normal expression of Aquaporin-1 protein on the erythrocyte membrane, resulting in the absence of Co... a Antigen, and no Co b The antigen was identified as the Co(a-b-) phenotype. This provides a genetic variation basis for the establishment of rare blood type banks and the assurance of transfusion compatibility, and can be used for Co(a-b-) blood type identification. The identification of the new allele also provides a new research target for exploring the association mechanism between Colton blood type and certain diseases, contributing to the optimization of personalized medicine strategies.

The invention belongs to the technical field of biological medicines and nano materials, and particularly relates to a composite nano particle for treating atherosclerosis as well as a preparation method and application of the composite nano particle. According to the composite nanoparticle, polydopamine nanoparticles serve as a core carrier, gold nanoparticles and probucol are loaded, and the outermost layer is coated with erythrocyte membrane vesicles. According to the invention, the active oxygen scavenging ability of the polydopamine nanoparticles, the enzyme-like catalytic activity of the gold nanoparticles, the lipid-lowering and anti-inflammatory effects of probucol, and the immune escape and focus targeting functions of the erythrocyte membrane are utilized to generate a synergistically enhanced treatment effect. The composite nanoparticles are good in biocompatibility and high in targeting property, can be efficiently enriched at atherosclerotic plaques, remarkably improve the treatment effect and reduce side effects, and have wide application prospects in preparation of atherosclerotic treatment drugs.